Vanguard Group’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,468,802
| Closed | -$2.2M | – | 4602 |
|
|
2023
Q1 | $2.2M | Buy |
1,468,802
+37,456
| +3% | +$50.4K | ﹤0.01% | 3634 |
|
|
2022
Q4 | $1.43M | Sell |
1,431,346
-2,079
| -0.1% | -$2.8K | ﹤0.01% | 3789 |
|
|
2022
Q3 | $2.58M | Buy |
1,433,425
+99,066
| +7% | +$287K | ﹤0.01% | 3640 |
|
|
2022
Q2 | $3.87M | Buy |
1,334,359
+303,462
| +29% | +$749K | ﹤0.01% | 3513 |
|
|
2022
Q1 | $2.85M | Sell |
1,030,897
-319,880
| -24% | -$1.01M | ﹤0.01% | 3801 |
|
|
2021
Q4 | $6.29M | Sell |
1,350,777
-103,295
| -7% | -$646K | ﹤0.01% | 3486 |
|
|
2021
Q3 | $12.4M | Buy |
1,454,072
+64,712
| +5% | +$914K | ﹤0.01% | 3124 |
|
|
2021
Q2 | $22.8M | Buy |
1,389,360
+17,857
| +1% | +$361K | ﹤0.01% | 2770 |
|
|
2021
Q1 | $30.3M | Buy |
1,371,503
+235,181
| +21% | +$6.41M | ﹤0.01% | 2589 |
|
|
2020
Q4 | $35.1M | Buy |
1,136,322
+47,231
| +4% | +$1.19M | ﹤0.01% | 2375 |
|
|
2020
Q3 | $22.1M | Buy |
1,089,091
+576,621
| +113% | +$10.1M | ﹤0.01% | 2405 |
|
|
2020
Q2 | $7.87M | Buy |
512,470
+25,467
| +5% | +$294K | ﹤0.01% | 2877 |
|
|
2020
Q1 | $3.77M | Buy |
487,003
+8,748
| +2% | +$107K | ﹤0.01% | 3092 |
|
|
2019
Q4 | $6.83M | Buy |
478,255
+12,886
| +3% | +$199K | ﹤0.01% | 3049 |
|
|
2019
Q3 | $6.99M | Buy |
465,369
+390,590
| +522% | +$6.08M | ﹤0.01% | 3008 |
|
|
2019
Q2 | $1.07M | Buy |
+74,779
| New | +$1.19M | ﹤0.01% | 3656 |
|
Vanguard Group's TCRR Position: Q2 2023 in Review
Vanguard Group sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 1,468,802 shares — an estimated $2.2M sold.
Vanguard Group first reported a position in TCRR in Q2 2019 and held it in 16 quarters. The position peaked at $35.1M in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- Vanguard Group reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Vanguard Group sold 1,468,802 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $2.2M.
- Vanguard Group first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2019 and held it in 16 quarters.
- Vanguard Group's TCR2 Therapeutics Inc. Common Stock position peaked at $35.1M in Q4 2020.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on Vanguard Group's 13F filing for Q2 2023, filed 14 Aug 2023.